[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"$fogvEMGTPuPgY3vywMEqMb2DLPrSHqIyuOUAmLyrEhF8":3},{"sponsor":4,"sponsorVariants":5,"totalTrials":6,"truncated":7,"activeTrials":8,"phase3Count":9,"totalEnrollment":10,"activePrograms":9,"nonDrugCount":11,"topConditions":12,"upcomingReadouts":34,"phaseBuckets":60,"rows":67},"Cliniques universitaires Saint-Luc- Université Catholique de Louvain",[4],340,false,52,6,54058,261,[13,16,19,22,24,27,29,32],{"name":14,"count":15},"Healthy",19,{"name":17,"count":18},"Cystic Fibrosis",14,{"name":20,"count":21},"Stroke",11,{"name":23,"count":9},"Surgery",{"name":25,"count":26},"Parkinson Disease",5,{"name":28,"count":26},"Head and Neck Cancer",{"name":30,"count":31},"Congenital Heart Disease",4,{"name":33,"count":31},"Covid19",[35,40,45,50,55],{"nctId":36,"briefTitle":37,"date":38,"intervention":39},"NCT04804683","European\u002FInternational FMD Registry and Initiative","2022-12-31","Genetic dissection of Fibromuscular Dysplasia",{"nctId":41,"briefTitle":42,"date":43,"intervention":44},"NCT02638389","Efficacy and Safety of Sirolimus in Vascular Anomalies That Are Refractory to Standard Care","2025-04-01","Sirolimus",{"nctId":46,"briefTitle":47,"date":48,"intervention":49},"NCT05369949","DEX vs SEVO in Congenital Heart Surgery","2025-12-30","DEX group",{"nctId":51,"briefTitle":52,"date":53,"intervention":54},"NCT03835520","Prospective Collection of Tumor Biopsy and Plasma Samples From Cancer Patients Treated With Molecular Targeted Therapies or Immunotherapy","2028-05","Immunotherapeutic Agent",{"nctId":56,"briefTitle":57,"date":58,"intervention":59},"NCT03197350","Characterization of Heart Failure With Preserved Ejection Fraction","2028-12","biomarker",[61,62,63,64,65,66],"EARLY_PHASE1","PHASE1","PHASE2","PHASE3","PHASE4","NA",[68,93,127,151,169,193,215,251,276,301,328,353,380,398,425,443,467,493,518,543,571,596,614,662,692,714,739,765,795,813,840,858,876,901,926,948,973,996,1022,1040,1058,1076,1102,1120,1138,1156,1182,1200,1218,1242,1266,1289,1307,1325,1347,1371,1396,1422,1440,1464,1489,1511,1536,1558,1583,1608,1635,1659,1682,1727,1754,1778,1804,1829,1856,1874,1897,1922,1940,1964,1990,2014,2036,2058,2085,2107,2132,2150,2175,2200,2218,2242,2267,2290,2315,2333],{"intervention":49,"totalTrials":69,"cells":70},1,{"EARLY_PHASE1":71,"PHASE1":74,"PHASE2":76,"PHASE3":78,"PHASE4":80,"NA":91},{"trials":72,"activeCount":73},[],0,{"trials":75,"activeCount":73},[],{"trials":77,"activeCount":73},[],{"trials":79,"activeCount":73},[],{"trials":81,"activeCount":69,"soonestReadout":48},[82],{"nctId":46,"briefTitle":47,"status":83,"phases":84,"primaryCompletion":48,"completion":85,"start":86,"enrollment":87,"conditions":88,"interventions":90},"NOT_YET_RECRUITING",[65],"2026-06-30","2023-01-05",150,[89],"Heart Defects, Congenital",[49],{"trials":92,"activeCount":73},[],{"intervention":44,"totalTrials":94,"cells":95},2,{"EARLY_PHASE1":96,"PHASE1":98,"PHASE2":100,"PHASE3":102,"PHASE4":123,"NA":125},{"trials":97,"activeCount":73},[],{"trials":99,"activeCount":73},[],{"trials":101,"activeCount":73},[],{"trials":103,"activeCount":69,"soonestReadout":43},[104,113],{"nctId":41,"briefTitle":42,"status":105,"phases":106,"primaryCompletion":43,"completion":107,"start":108,"enrollment":109,"conditions":110,"interventions":112},"RECRUITING",[64],"2030-04-01","2016-01-25",250,[111],"Vascular Malformations",[44],{"nctId":114,"briefTitle":115,"status":116,"phases":117,"primaryCompletion":118,"completion":118,"start":119,"enrollment":15,"conditions":120,"interventions":122},"NCT01811667","Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations","COMPLETED",[64],"2016-01","2012-05",[121],"Cardiovascular Abnormalities",[44],{"trials":124,"activeCount":73},[],{"trials":126,"activeCount":73},[],{"intervention":54,"totalTrials":69,"cells":128},{"EARLY_PHASE1":129,"PHASE1":131,"PHASE2":133,"PHASE3":135,"PHASE4":137,"NA":139},{"trials":130,"activeCount":73},[],{"trials":132,"activeCount":73},[],{"trials":134,"activeCount":73},[],{"trials":136,"activeCount":73},[],{"trials":138,"activeCount":73},[],{"trials":140,"activeCount":69,"soonestReadout":53},[141],{"nctId":51,"briefTitle":52,"status":142,"phases":143,"primaryCompletion":53,"completion":144,"start":145,"enrollment":146,"conditions":147,"interventions":149},"ACTIVE_NOT_RECRUITING",[66],"2028-05-01","2018-07-11",200,[148],"Cancer",[54,150],"Molecular Target",{"intervention":150,"totalTrials":69,"cells":152},{"EARLY_PHASE1":153,"PHASE1":155,"PHASE2":157,"PHASE3":159,"PHASE4":161,"NA":163},{"trials":154,"activeCount":73},[],{"trials":156,"activeCount":73},[],{"trials":158,"activeCount":73},[],{"trials":160,"activeCount":73},[],{"trials":162,"activeCount":73},[],{"trials":164,"activeCount":69,"soonestReadout":53},[165],{"nctId":51,"briefTitle":52,"status":142,"phases":166,"primaryCompletion":53,"completion":144,"start":145,"enrollment":146,"conditions":167,"interventions":168},[66],[148],[54,150],{"intervention":59,"totalTrials":69,"cells":170},{"EARLY_PHASE1":171,"PHASE1":173,"PHASE2":175,"PHASE3":177,"PHASE4":179,"NA":181},{"trials":172,"activeCount":73},[],{"trials":174,"activeCount":73},[],{"trials":176,"activeCount":73},[],{"trials":178,"activeCount":73},[],{"trials":180,"activeCount":73},[],{"trials":182,"activeCount":69,"soonestReadout":58},[183],{"nctId":56,"briefTitle":57,"status":105,"phases":184,"primaryCompletion":58,"completion":58,"start":185,"enrollment":186,"conditions":187,"interventions":192},[66],"2014-12-04",500,[188,189,190,191],"Heart Failure, Preserved Ejection Fraction","Cardiac Fibrosis","Biomarkers","Magnetic Resonance Imaging",[59],{"intervention":39,"totalTrials":69,"cells":194},{"EARLY_PHASE1":195,"PHASE1":197,"PHASE2":199,"PHASE3":201,"PHASE4":203,"NA":205},{"trials":196,"activeCount":73},[],{"trials":198,"activeCount":73},[],{"trials":200,"activeCount":73},[],{"trials":202,"activeCount":73},[],{"trials":204,"activeCount":73},[],{"trials":206,"activeCount":69,"soonestReadout":38},[207],{"nctId":36,"briefTitle":37,"status":105,"phases":208,"primaryCompletion":38,"completion":209,"start":210,"enrollment":211,"conditions":212,"interventions":214},[66],"2031-03-10","2021-03-11",5000,[213],"Fibromuscular Dysplasia",[39],{"intervention":216,"totalTrials":94,"cells":217},"Dexmedetomidine",{"EARLY_PHASE1":218,"PHASE1":220,"PHASE2":222,"PHASE3":224,"PHASE4":226,"NA":249},{"trials":219,"activeCount":73},[],{"trials":221,"activeCount":73},[],{"trials":223,"activeCount":73},[],{"trials":225,"activeCount":73},[],{"trials":227,"activeCount":73},[228,238],{"nctId":229,"briefTitle":230,"status":116,"phases":231,"primaryCompletion":232,"completion":232,"start":233,"enrollment":234,"conditions":235,"interventions":237},"NCT03388541","Low Dose Dexmedetomidine and Delirium After Cardiac Surgery",[65],"2019-08-12","2018-01-17",420,[236],"Cardiac Surgical Procedures",[216],{"nctId":239,"briefTitle":240,"status":116,"phases":241,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":245,"interventions":247},"NCT02358057","Can we Get Conscious Sedation by Combining Dexmedetomidine With Alfentanil?",[65],"2016-04","2015-02",40,[246],"Procedural Sedation",[216,248],"Alfentanil",{"trials":250,"activeCount":73},[],{"intervention":252,"totalTrials":69,"cells":253},"exenatide",{"EARLY_PHASE1":254,"PHASE1":256,"PHASE2":258,"PHASE3":260,"PHASE4":262,"NA":274},{"trials":255,"activeCount":73},[],{"trials":257,"activeCount":73},[],{"trials":259,"activeCount":73},[],{"trials":261,"activeCount":73},[],{"trials":263,"activeCount":73},[264],{"nctId":265,"briefTitle":266,"status":116,"phases":267,"primaryCompletion":268,"completion":268,"start":269,"enrollment":270,"conditions":271,"interventions":273},"NCT00948168","Effect of Exenatide on Glucose Homeostasis Determinants in Type 2 Diabetes",[65],"2009-07","2008-07",34,[272],"Type 2 Diabetes Mellitus",[252],{"trials":275,"activeCount":73},[],{"intervention":277,"totalTrials":69,"cells":278},"Blood samples for DOAC measurement",{"EARLY_PHASE1":279,"PHASE1":281,"PHASE2":283,"PHASE3":285,"PHASE4":287,"NA":299},{"trials":280,"activeCount":73},[],{"trials":282,"activeCount":73},[],{"trials":284,"activeCount":73},[],{"trials":286,"activeCount":73},[],{"trials":288,"activeCount":73},[289],{"nctId":290,"briefTitle":291,"status":116,"phases":292,"primaryCompletion":118,"start":293,"enrollment":294,"conditions":295,"interventions":298},"NCT02720328","Prevalence and Causes of Preventable and Serious Adverse Drug Reactions Related to the Use of Oral Anticoagulants",[65],"2015-07",102,[296,297],"Embolism and Thrombosis","Hemorrhage",[277],{"trials":300,"activeCount":73},[],{"intervention":302,"totalTrials":69,"cells":303},"patients with sunitinib or pazopanib",{"EARLY_PHASE1":304,"PHASE1":306,"PHASE2":308,"PHASE3":310,"PHASE4":312,"NA":326},{"trials":305,"activeCount":73},[],{"trials":307,"activeCount":73},[],{"trials":309,"activeCount":73},[],{"trials":311,"activeCount":73},[],{"trials":313,"activeCount":73},[314],{"nctId":315,"briefTitle":316,"status":317,"phases":318,"primaryCompletion":319,"completion":320,"start":321,"enrollment":322,"conditions":323,"interventions":325},"NCT02570789","Evaluation of Predictive Markers for Toxicity and Efficacy in Patients With mccRCC Treated by Anti-VEGF Therapy","TERMINATED",[65],"2018-12","2021-03-01","2012-12",90,[324],"Clear-cell Metastatic Renal Cell Carcinoma",[302],{"trials":327,"activeCount":73},[],{"intervention":329,"totalTrials":69,"cells":330},"recFSH",{"EARLY_PHASE1":331,"PHASE1":333,"PHASE2":335,"PHASE3":337,"PHASE4":339,"NA":351},{"trials":332,"activeCount":73},[],{"trials":334,"activeCount":73},[],{"trials":336,"activeCount":73},[],{"trials":338,"activeCount":73},[],{"trials":340,"activeCount":73},[341],{"nctId":342,"briefTitle":343,"status":344,"phases":345,"primaryCompletion":346,"completion":346,"start":118,"enrollment":347,"conditions":348,"interventions":350},"NCT02430740","Tailored Ovarian Stimulation Based on BMI, AMH, AFC","UNKNOWN",[65],"2023-12",300,[349],"Infertility",[329],{"trials":352,"activeCount":73},[],{"intervention":354,"totalTrials":69,"cells":355},"Randomisation to omalizumab",{"EARLY_PHASE1":356,"PHASE1":358,"PHASE2":360,"PHASE3":362,"PHASE4":364,"NA":378},{"trials":357,"activeCount":73},[],{"trials":359,"activeCount":73},[],{"trials":361,"activeCount":73},[],{"trials":363,"activeCount":73},[],{"trials":365,"activeCount":73},[366],{"nctId":367,"briefTitle":368,"status":344,"phases":369,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":374,"interventions":376},"NCT03476109","Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.",[65],"2023-12-31","2024-12-31","2019-05-10",100,[375],"Severe Asthma",[354,377],"Randomisation to mepolizumab",{"trials":379,"activeCount":73},[],{"intervention":377,"totalTrials":69,"cells":381},{"EARLY_PHASE1":382,"PHASE1":384,"PHASE2":386,"PHASE3":388,"PHASE4":390,"NA":396},{"trials":383,"activeCount":73},[],{"trials":385,"activeCount":73},[],{"trials":387,"activeCount":73},[],{"trials":389,"activeCount":73},[],{"trials":391,"activeCount":73},[392],{"nctId":367,"briefTitle":368,"status":344,"phases":393,"primaryCompletion":370,"completion":371,"start":372,"enrollment":373,"conditions":394,"interventions":395},[65],[375],[354,377],{"trials":397,"activeCount":73},[],{"intervention":399,"totalTrials":69,"cells":400},"Sandostatin",{"EARLY_PHASE1":401,"PHASE1":403,"PHASE2":405,"PHASE3":407,"PHASE4":409,"NA":423},{"trials":402,"activeCount":73},[],{"trials":404,"activeCount":73},[],{"trials":406,"activeCount":73},[],{"trials":408,"activeCount":73},[],{"trials":410,"activeCount":73},[411],{"nctId":412,"briefTitle":413,"status":317,"phases":414,"primaryCompletion":415,"completion":416,"start":417,"enrollment":418,"conditions":419,"interventions":422},"NCT04140409","Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation",[65],"2019-06-30","2019-09-19","2016-02-02",10,[420,421],"Neuroendocrine Tumors","Carcinoid Syndrome",[399],{"trials":424,"activeCount":73},[],{"intervention":248,"totalTrials":69,"cells":426},{"EARLY_PHASE1":427,"PHASE1":429,"PHASE2":431,"PHASE3":433,"PHASE4":435,"NA":441},{"trials":428,"activeCount":73},[],{"trials":430,"activeCount":73},[],{"trials":432,"activeCount":73},[],{"trials":434,"activeCount":73},[],{"trials":436,"activeCount":73},[437],{"nctId":239,"briefTitle":240,"status":116,"phases":438,"primaryCompletion":242,"completion":242,"start":243,"enrollment":244,"conditions":439,"interventions":440},[65],[246],[216,248],{"trials":442,"activeCount":73},[],{"intervention":444,"totalTrials":69,"cells":445},"Ketalar, 5 mg\u002FmL Injectable Solution",{"EARLY_PHASE1":446,"PHASE1":448,"PHASE2":450,"PHASE3":452,"PHASE4":454,"NA":465},{"trials":447,"activeCount":73},[],{"trials":449,"activeCount":73},[],{"trials":451,"activeCount":73},[],{"trials":453,"activeCount":73},[],{"trials":455,"activeCount":73},[456],{"nctId":457,"briefTitle":458,"status":344,"phases":459,"primaryCompletion":460,"completion":461,"start":462,"enrollment":373,"conditions":463,"interventions":464},"NCT04890418","Risk Factors and Prevention of Severe Pain Upon Cessation of a Peripheral Nerve Block",[65],"2021-05-31","2021-07-01","2020-01-01",[23],[444],{"trials":466,"activeCount":73},[],{"intervention":468,"totalTrials":69,"cells":469},"Tacrolimus",{"EARLY_PHASE1":470,"PHASE1":472,"PHASE2":474,"PHASE3":476,"PHASE4":478,"NA":491},{"trials":471,"activeCount":73},[],{"trials":473,"activeCount":73},[],{"trials":475,"activeCount":73},[],{"trials":477,"activeCount":73},[],{"trials":479,"activeCount":73},[480],{"nctId":481,"briefTitle":482,"status":344,"phases":483,"primaryCompletion":484,"completion":485,"start":486,"enrollment":487,"conditions":488,"interventions":490},"NCT02064777","Prospective Tacrolimus Pharmacokinetics Study in Pediatric Living Donor Liver Transplantation",[65],"2014-06","2014-09","2013-07",60,[489],"Pediatric Liver Transplantation",[468],{"trials":492,"activeCount":73},[],{"intervention":494,"totalTrials":69,"cells":495},"O.M.T",{"EARLY_PHASE1":496,"PHASE1":498,"PHASE2":500,"PHASE3":502,"PHASE4":514,"NA":516},{"trials":497,"activeCount":73},[],{"trials":499,"activeCount":73},[],{"trials":501,"activeCount":73},[],{"trials":503,"activeCount":73},[504],{"nctId":505,"briefTitle":506,"status":116,"phases":507,"primaryCompletion":508,"completion":508,"start":509,"enrollment":510,"conditions":511,"interventions":513},"NCT02982057","Non Culprit Lesion Study",[64],"2019-11-01","2015-01",50,[512],"STEMI",[494],{"trials":515,"activeCount":73},[],{"trials":517,"activeCount":73},[],{"intervention":519,"totalTrials":69,"cells":520},"Botulinum toxin",{"EARLY_PHASE1":521,"PHASE1":523,"PHASE2":525,"PHASE3":527,"PHASE4":539,"NA":541},{"trials":522,"activeCount":73},[],{"trials":524,"activeCount":73},[],{"trials":526,"activeCount":73},[],{"trials":528,"activeCount":73},[529],{"nctId":530,"briefTitle":531,"status":116,"phases":532,"primaryCompletion":533,"completion":533,"start":534,"enrollment":535,"conditions":536,"interventions":538},"NCT00825097","Efficacy Study of Selective Tibial Neurotomy in the Treatment of the Spastic Equinovarus Foot Among Adult Hemiplegic Patients",[64],"2011-12","2008-10",16,[537,20],"Spastic Equinovarus Foot",[519],{"trials":540,"activeCount":73},[],{"trials":542,"activeCount":73},[],{"intervention":544,"totalTrials":69,"cells":545},"Oxygen",{"EARLY_PHASE1":546,"PHASE1":548,"PHASE2":550,"PHASE3":552,"PHASE4":567,"NA":569},{"trials":547,"activeCount":73},[],{"trials":549,"activeCount":73},[],{"trials":551,"activeCount":73},[],{"trials":553,"activeCount":73},[554],{"nctId":555,"briefTitle":556,"status":344,"phases":557,"primaryCompletion":558,"completion":559,"start":560,"enrollment":487,"conditions":561,"interventions":566},"NCT05430620","Intermittent Versus Continuous Surface O2 During HMP of DCD Kidneys",[64],"2025-01-01","2026-01-01","2022-03-20",[562,563,564,565],"Delayed Graft Function","Kidney Transplant; Complications","Ischemia Reperfusion Injury","Mitochondrial",[544],{"trials":568,"activeCount":73},[],{"trials":570,"activeCount":73},[],{"intervention":572,"totalTrials":69,"cells":573},"methylprednisolone",{"EARLY_PHASE1":574,"PHASE1":576,"PHASE2":578,"PHASE3":580,"PHASE4":592,"NA":594},{"trials":575,"activeCount":73},[],{"trials":577,"activeCount":73},[],{"trials":579,"activeCount":73},[],{"trials":581,"activeCount":73},[582],{"nctId":583,"briefTitle":584,"status":116,"phases":585,"primaryCompletion":586,"completion":587,"start":486,"enrollment":510,"conditions":588,"interventions":590},"NCT01907204","Evaluation of Inhaled Treatment in Sinusitis",[63,64],"2013-08","2014-01",[589],"Sinusitis",[572,591,591],"Budesonide",{"trials":593,"activeCount":73},[],{"trials":595,"activeCount":73},[],{"intervention":591,"totalTrials":69,"cells":597},{"EARLY_PHASE1":598,"PHASE1":600,"PHASE2":602,"PHASE3":604,"PHASE4":610,"NA":612},{"trials":599,"activeCount":73},[],{"trials":601,"activeCount":73},[],{"trials":603,"activeCount":73},[],{"trials":605,"activeCount":73},[606],{"nctId":583,"briefTitle":584,"status":116,"phases":607,"primaryCompletion":586,"completion":587,"start":486,"enrollment":510,"conditions":608,"interventions":609},[63,64],[589],[572,591,591],{"trials":611,"activeCount":73},[],{"trials":613,"activeCount":73},[],{"intervention":615,"totalTrials":616,"cells":617},"Irinotecan",3,{"EARLY_PHASE1":618,"PHASE1":620,"PHASE2":622,"PHASE3":656,"PHASE4":658,"NA":660},{"trials":619,"activeCount":73},[],{"trials":621,"activeCount":73},[],{"trials":623,"activeCount":73},[624,636,647],{"nctId":625,"briefTitle":626,"status":116,"phases":627,"primaryCompletion":628,"completion":628,"start":629,"enrollment":487,"conditions":630,"interventions":632},"NCT01858649","Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Bevacizumab With FOLFOX or FOLFIRI.",[63],"2019-05","2013-05",[631],"Metastatic Colorectal Cancer",[633,634,635,615],"Bevacizumab","5 FU","Oxaliplatin",{"nctId":637,"briefTitle":638,"status":344,"phases":639,"primaryCompletion":370,"completion":370,"start":640,"enrollment":641,"conditions":642,"interventions":644},"NCT03608046","Avelumab Combined With Cetuximab and Irinotecan for Treatment Refractory Metastatic Colorectal Microsatellite Stable Cancer",[63],"2018-10-03",59,[643],"Colorectal Neoplasms, Malignant",[645,646,615],"Avelumab","Cetuximab",{"nctId":648,"briefTitle":649,"status":317,"phases":650,"primaryCompletion":651,"completion":651,"start":587,"enrollment":31,"conditions":652,"interventions":653},"NCT01858662","Study Comparing Pathological Responses Observed on Colorectal Cancer Metastases Resected After Preoperative Treatment Combining Cetuximab With FOLFOX or FOLFIRI in RAS and B-RAF WT Tumors",[63],"2015-11",[631],[654,655,635,615,646],"5-Fluorouracile","leucovorin L",{"trials":657,"activeCount":73},[],{"trials":659,"activeCount":73},[],{"trials":661,"activeCount":73},[],{"intervention":646,"totalTrials":616,"cells":663},{"EARLY_PHASE1":664,"PHASE1":666,"PHASE2":668,"PHASE3":686,"PHASE4":688,"NA":690},{"trials":665,"activeCount":73},[],{"trials":667,"activeCount":73},[],{"trials":669,"activeCount":73},[670,674,678],{"nctId":637,"briefTitle":638,"status":344,"phases":671,"primaryCompletion":370,"completion":370,"start":640,"enrollment":641,"conditions":672,"interventions":673},[63],[643],[645,646,615],{"nctId":648,"briefTitle":649,"status":317,"phases":675,"primaryCompletion":651,"completion":651,"start":587,"enrollment":31,"conditions":676,"interventions":677},[63],[631],[654,655,635,615,646],{"nctId":679,"briefTitle":680,"status":116,"phases":681,"primaryCompletion":682,"completion":682,"start":269,"enrollment":270,"conditions":683,"interventions":684},"NCT00714649","Neoadjuvant Cetuximab in HNSCC Combined With Curative Surgery",[62,63],"2011-05",[28],[685],"cetuximab",{"trials":687,"activeCount":73},[],{"trials":689,"activeCount":73},[],{"trials":691,"activeCount":73},[],{"intervention":635,"totalTrials":94,"cells":693},{"EARLY_PHASE1":694,"PHASE1":696,"PHASE2":698,"PHASE3":708,"PHASE4":710,"NA":712},{"trials":695,"activeCount":73},[],{"trials":697,"activeCount":73},[],{"trials":699,"activeCount":73},[700,704],{"nctId":625,"briefTitle":626,"status":116,"phases":701,"primaryCompletion":628,"completion":628,"start":629,"enrollment":487,"conditions":702,"interventions":703},[63],[631],[633,634,635,615],{"nctId":648,"briefTitle":649,"status":317,"phases":705,"primaryCompletion":651,"completion":651,"start":587,"enrollment":31,"conditions":706,"interventions":707},[63],[631],[654,655,635,615,646],{"trials":709,"activeCount":73},[],{"trials":711,"activeCount":73},[],{"trials":713,"activeCount":73},[],{"intervention":715,"totalTrials":69,"cells":716},"Doxorubicin",{"EARLY_PHASE1":717,"PHASE1":719,"PHASE2":721,"PHASE3":733,"PHASE4":735,"NA":737},{"trials":718,"activeCount":73},[],{"trials":720,"activeCount":73},[],{"trials":722,"activeCount":73},[723],{"nctId":724,"briefTitle":725,"status":317,"phases":726,"primaryCompletion":727,"completion":727,"start":728,"enrollment":616,"conditions":729,"interventions":732},"NCT02958163","Clinical Trial Comparing TACE With TACE + SABR in Stage BCLC B HCC (HepSTAR)",[63],"2017-10-17","2017-02-20",[730,731],"Liver Neoplasms","Hepatocellular Cancer",[715],{"trials":734,"activeCount":73},[],{"trials":736,"activeCount":73},[],{"trials":738,"activeCount":73},[],{"intervention":740,"totalTrials":69,"cells":741},"Temozolomide",{"EARLY_PHASE1":742,"PHASE1":744,"PHASE2":746,"PHASE3":759,"PHASE4":761,"NA":763},{"trials":743,"activeCount":73},[],{"trials":745,"activeCount":73},[],{"trials":747,"activeCount":73},[748],{"nctId":749,"briefTitle":750,"status":344,"phases":751,"primaryCompletion":752,"completion":753,"start":754,"enrollment":755,"conditions":756,"interventions":758},"NCT00643825","Prolonged Adjuvant Temozolomide vs \"Stop & Go\" in Glioblastoma Patients",[63],"2011-01","2012-01","2008-01",64,[757],"Glioblastoma",[740,740],{"trials":760,"activeCount":73},[],{"trials":762,"activeCount":73},[],{"trials":764,"activeCount":73},[],{"intervention":766,"totalTrials":69,"cells":767},"IO102",{"EARLY_PHASE1":768,"PHASE1":770,"PHASE2":772,"PHASE3":789,"PHASE4":791,"NA":793},{"trials":769,"activeCount":73},[],{"trials":771,"activeCount":73},[],{"trials":773,"activeCount":73},[774],{"nctId":775,"briefTitle":776,"status":317,"phases":777,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":782,"interventions":787},"NCT04445064","Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.",[63],"2024-06-08","2025-03-20","2020-08-14",17,[783,784,785,786],"Oropharynx Squamous Cell Carcinoma","Larynx Squamous Cell Carcinoma","Hypopharynx Squamous Cell Carcinoma","Oral Cavity Squamous Cell Carcinoma",[766,788],"IO103",{"trials":790,"activeCount":73},[],{"trials":792,"activeCount":73},[],{"trials":794,"activeCount":73},[],{"intervention":788,"totalTrials":69,"cells":796},{"EARLY_PHASE1":797,"PHASE1":799,"PHASE2":801,"PHASE3":807,"PHASE4":809,"NA":811},{"trials":798,"activeCount":73},[],{"trials":800,"activeCount":73},[],{"trials":802,"activeCount":73},[803],{"nctId":775,"briefTitle":776,"status":317,"phases":804,"primaryCompletion":778,"completion":779,"start":780,"enrollment":781,"conditions":805,"interventions":806},[63],[783,784,785,786],[766,788],{"trials":808,"activeCount":73},[],{"trials":810,"activeCount":73},[],{"trials":812,"activeCount":73},[],{"intervention":814,"totalTrials":69,"cells":815},"docetaxel",{"EARLY_PHASE1":816,"PHASE1":818,"PHASE2":820,"PHASE3":834,"PHASE4":836,"NA":838},{"trials":817,"activeCount":73},[],{"trials":819,"activeCount":73},[],{"trials":821,"activeCount":73},[822],{"nctId":823,"briefTitle":824,"status":116,"phases":825,"completion":826,"start":827,"enrollment":87,"conditions":828,"interventions":831},"NCT00541281","Safety and Efficacy Study of of Docetaxel vs Docetaxel Estramustine in Hormone Refractory Prostatic Cancer",[63],"2006-02","2003-12",[829,830],"Hormone Resistant Prostate Cancer","Metastatic Prostate Cancer",[814,832,833],"estramustine","prednisone",{"trials":835,"activeCount":73},[],{"trials":837,"activeCount":73},[],{"trials":839,"activeCount":73},[],{"intervention":832,"totalTrials":69,"cells":841},{"EARLY_PHASE1":842,"PHASE1":844,"PHASE2":846,"PHASE3":852,"PHASE4":854,"NA":856},{"trials":843,"activeCount":73},[],{"trials":845,"activeCount":73},[],{"trials":847,"activeCount":73},[848],{"nctId":823,"briefTitle":824,"status":116,"phases":849,"completion":826,"start":827,"enrollment":87,"conditions":850,"interventions":851},[63],[829,830],[814,832,833],{"trials":853,"activeCount":73},[],{"trials":855,"activeCount":73},[],{"trials":857,"activeCount":73},[],{"intervention":833,"totalTrials":69,"cells":859},{"EARLY_PHASE1":860,"PHASE1":862,"PHASE2":864,"PHASE3":870,"PHASE4":872,"NA":874},{"trials":861,"activeCount":73},[],{"trials":863,"activeCount":73},[],{"trials":865,"activeCount":73},[866],{"nctId":823,"briefTitle":824,"status":116,"phases":867,"completion":826,"start":827,"enrollment":87,"conditions":868,"interventions":869},[63],[829,830],[814,832,833],{"trials":871,"activeCount":73},[],{"trials":873,"activeCount":73},[],{"trials":875,"activeCount":73},[],{"intervention":877,"totalTrials":69,"cells":878},"Theravac",{"EARLY_PHASE1":879,"PHASE1":881,"PHASE2":883,"PHASE3":895,"PHASE4":897,"NA":899},{"trials":880,"activeCount":73},[],{"trials":882,"activeCount":73},[],{"trials":884,"activeCount":73},[885],{"nctId":886,"briefTitle":887,"status":344,"phases":888,"primaryCompletion":889,"start":890,"enrollment":891,"conditions":892,"interventions":894},"NCT01331915","Safety and Toxicity Study of Vaccination for Advanced Metastatic Melanoma Patients",[62,63],"2013-10","2010-09",23,[893],"Melanoma",[877],{"trials":896,"activeCount":73},[],{"trials":898,"activeCount":73},[],{"trials":900,"activeCount":73},[],{"intervention":902,"totalTrials":69,"cells":903},"Radiotherapy",{"EARLY_PHASE1":904,"PHASE1":906,"PHASE2":908,"PHASE3":920,"PHASE4":922,"NA":924},{"trials":905,"activeCount":73},[],{"trials":907,"activeCount":73},[],{"trials":909,"activeCount":73},[910],{"nctId":911,"briefTitle":912,"status":116,"phases":913,"primaryCompletion":914,"completion":914,"start":915,"enrollment":916,"conditions":917,"interventions":919},"NCT00389727","Simultaneous Integrated Boost (SIB)- IMRT",[63],"2008-05-26","2004-09-24",22,[918],"Carcinoma, Squamous Cell",[902],{"trials":921,"activeCount":73},[],{"trials":923,"activeCount":73},[],{"trials":925,"activeCount":73},[],{"intervention":927,"totalTrials":69,"cells":928},"Miglustat",{"EARLY_PHASE1":929,"PHASE1":931,"PHASE2":933,"PHASE3":942,"PHASE4":944,"NA":946},{"trials":930,"activeCount":73},[],{"trials":932,"activeCount":73},[],{"trials":934,"activeCount":73},[935],{"nctId":936,"briefTitle":937,"status":116,"phases":938,"primaryCompletion":682,"completion":939,"start":268,"enrollment":418,"conditions":940,"interventions":941},"NCT00945347","Does a Nasal Instillation of Miglustat Normalize the Nasal Potential Difference in Cystic Fibrosis Patients ?",[63],"2011-06",[17],[927],{"trials":943,"activeCount":73},[],{"trials":945,"activeCount":73},[],{"trials":947,"activeCount":73},[],{"intervention":949,"totalTrials":69,"cells":950},"panitumumab",{"EARLY_PHASE1":951,"PHASE1":953,"PHASE2":955,"PHASE3":967,"PHASE4":969,"NA":971},{"trials":952,"activeCount":73},[],{"trials":954,"activeCount":73},[],{"trials":956,"activeCount":73},[957],{"nctId":958,"briefTitle":959,"status":317,"phases":960,"primaryCompletion":961,"completion":321,"start":962,"enrollment":963,"conditions":964,"interventions":966},"NCT00973193","Preoperative Panitumumab and Radiotherapy in Rectal Cancer",[63],"2011-09","2009-09",20,[965],"Rectal Cancer",[949],{"trials":968,"activeCount":73},[],{"trials":970,"activeCount":73},[],{"trials":972,"activeCount":73},[],{"intervention":974,"totalTrials":69,"cells":975},"CP-751,871",{"EARLY_PHASE1":976,"PHASE1":978,"PHASE2":980,"PHASE3":990,"PHASE4":992,"NA":994},{"trials":977,"activeCount":73},[],{"trials":979,"activeCount":73},[],{"trials":981,"activeCount":73},[982],{"nctId":983,"briefTitle":984,"status":317,"phases":985,"primaryCompletion":890,"completion":890,"start":986,"enrollment":987,"conditions":988,"interventions":989},"NCT00872404","A Study of CP-751,871 in Patients With Recurrent Squamous Head and Neck Carcinoma",[63],"2009-01",37,[28],[974],{"trials":991,"activeCount":73},[],{"trials":993,"activeCount":73},[],{"trials":995,"activeCount":73},[],{"intervention":997,"totalTrials":69,"cells":998},"Immunological peptides and immunological adjuvants",{"EARLY_PHASE1":999,"PHASE1":1001,"PHASE2":1003,"PHASE3":1016,"PHASE4":1018,"NA":1020},{"trials":1000,"activeCount":73},[],{"trials":1002,"activeCount":73},[],{"trials":1004,"activeCount":73},[1005],{"nctId":1006,"briefTitle":1007,"status":317,"phases":1008,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":15,"conditions":1011,"interventions":1012},"NCT00365937","Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides",[62,63],"2013-12-13","2006-08",[893],[997,1013,1014,1015],"HLA-A2 peptides","Montanide ISA51","IMP321",{"trials":1017,"activeCount":73},[],{"trials":1019,"activeCount":73},[],{"trials":1021,"activeCount":73},[],{"intervention":1013,"totalTrials":69,"cells":1023},{"EARLY_PHASE1":1024,"PHASE1":1026,"PHASE2":1028,"PHASE3":1034,"PHASE4":1036,"NA":1038},{"trials":1025,"activeCount":73},[],{"trials":1027,"activeCount":73},[],{"trials":1029,"activeCount":73},[1030],{"nctId":1006,"briefTitle":1007,"status":317,"phases":1031,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":15,"conditions":1032,"interventions":1033},[62,63],[893],[997,1013,1014,1015],{"trials":1035,"activeCount":73},[],{"trials":1037,"activeCount":73},[],{"trials":1039,"activeCount":73},[],{"intervention":1014,"totalTrials":69,"cells":1041},{"EARLY_PHASE1":1042,"PHASE1":1044,"PHASE2":1046,"PHASE3":1052,"PHASE4":1054,"NA":1056},{"trials":1043,"activeCount":73},[],{"trials":1045,"activeCount":73},[],{"trials":1047,"activeCount":73},[1048],{"nctId":1006,"briefTitle":1007,"status":317,"phases":1049,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":15,"conditions":1050,"interventions":1051},[62,63],[893],[997,1013,1014,1015],{"trials":1053,"activeCount":73},[],{"trials":1055,"activeCount":73},[],{"trials":1057,"activeCount":73},[],{"intervention":1015,"totalTrials":69,"cells":1059},{"EARLY_PHASE1":1060,"PHASE1":1062,"PHASE2":1064,"PHASE3":1070,"PHASE4":1072,"NA":1074},{"trials":1061,"activeCount":73},[],{"trials":1063,"activeCount":73},[],{"trials":1065,"activeCount":73},[1066],{"nctId":1006,"briefTitle":1007,"status":317,"phases":1067,"primaryCompletion":1009,"completion":1009,"start":1010,"enrollment":15,"conditions":1068,"interventions":1069},[62,63],[893],[997,1013,1014,1015],{"trials":1071,"activeCount":73},[],{"trials":1073,"activeCount":73},[],{"trials":1075,"activeCount":73},[],{"intervention":1077,"totalTrials":69,"cells":1078},"SU011248",{"EARLY_PHASE1":1079,"PHASE1":1081,"PHASE2":1083,"PHASE3":1096,"PHASE4":1098,"NA":1100},{"trials":1080,"activeCount":73},[],{"trials":1082,"activeCount":73},[],{"trials":1084,"activeCount":73},[1085],{"nctId":1086,"briefTitle":1087,"status":317,"phases":1088,"primaryCompletion":533,"completion":533,"start":1089,"enrollment":1090,"conditions":1091,"interventions":1095},"NCT00408252","Efficacy of SU 011248 in Head And Neck Carcinoma",[63],"2007-02",54,[1092,1093,1094],"Recurrent Disease","Squamous Cell Head and Neck Carcinoma","Palliative Treatment",[1077],{"trials":1097,"activeCount":73},[],{"trials":1099,"activeCount":73},[],{"trials":1101,"activeCount":73},[],{"intervention":633,"totalTrials":69,"cells":1103},{"EARLY_PHASE1":1104,"PHASE1":1106,"PHASE2":1108,"PHASE3":1114,"PHASE4":1116,"NA":1118},{"trials":1105,"activeCount":73},[],{"trials":1107,"activeCount":73},[],{"trials":1109,"activeCount":73},[1110],{"nctId":625,"briefTitle":626,"status":116,"phases":1111,"primaryCompletion":628,"completion":628,"start":629,"enrollment":487,"conditions":1112,"interventions":1113},[63],[631],[633,634,635,615],{"trials":1115,"activeCount":73},[],{"trials":1117,"activeCount":73},[],{"trials":1119,"activeCount":73},[],{"intervention":634,"totalTrials":69,"cells":1121},{"EARLY_PHASE1":1122,"PHASE1":1124,"PHASE2":1126,"PHASE3":1132,"PHASE4":1134,"NA":1136},{"trials":1123,"activeCount":73},[],{"trials":1125,"activeCount":73},[],{"trials":1127,"activeCount":73},[1128],{"nctId":625,"briefTitle":626,"status":116,"phases":1129,"primaryCompletion":628,"completion":628,"start":629,"enrollment":487,"conditions":1130,"interventions":1131},[63],[631],[633,634,635,615],{"trials":1133,"activeCount":73},[],{"trials":1135,"activeCount":73},[],{"trials":1137,"activeCount":73},[],{"intervention":645,"totalTrials":69,"cells":1139},{"EARLY_PHASE1":1140,"PHASE1":1142,"PHASE2":1144,"PHASE3":1150,"PHASE4":1152,"NA":1154},{"trials":1141,"activeCount":73},[],{"trials":1143,"activeCount":73},[],{"trials":1145,"activeCount":73},[1146],{"nctId":637,"briefTitle":638,"status":344,"phases":1147,"primaryCompletion":370,"completion":370,"start":640,"enrollment":641,"conditions":1148,"interventions":1149},[63],[643],[645,646,615],{"trials":1151,"activeCount":73},[],{"trials":1153,"activeCount":73},[],{"trials":1155,"activeCount":73},[],{"intervention":1157,"totalTrials":69,"cells":1158},"Tumor specific peptides: MAGE-3.A1 and \u002F or NA17.A2",{"EARLY_PHASE1":1159,"PHASE1":1161,"PHASE2":1163,"PHASE3":1176,"PHASE4":1178,"NA":1180},{"trials":1160,"activeCount":73},[],{"trials":1162,"activeCount":73},[],{"trials":1164,"activeCount":73},[1165],{"nctId":1166,"briefTitle":1167,"status":317,"phases":1168,"primaryCompletion":1169,"completion":1169,"start":1170,"enrollment":9,"conditions":1171,"interventions":1173},"NCT01723813","Peptide Vaccinations Plus GM-CT-01 in Melanoma",[62,63],"2015-04-01","2012-04",[1172],"Metastatic Melanoma",[1157,1174,1175],"Galectin-3 inhibitor: GM-CT-01 systemic injections","Galectin-3 inhibitor: GM-CT-01 Peri-tumoral administration",{"trials":1177,"activeCount":73},[],{"trials":1179,"activeCount":73},[],{"trials":1181,"activeCount":73},[],{"intervention":1174,"totalTrials":69,"cells":1183},{"EARLY_PHASE1":1184,"PHASE1":1186,"PHASE2":1188,"PHASE3":1194,"PHASE4":1196,"NA":1198},{"trials":1185,"activeCount":73},[],{"trials":1187,"activeCount":73},[],{"trials":1189,"activeCount":73},[1190],{"nctId":1166,"briefTitle":1167,"status":317,"phases":1191,"primaryCompletion":1169,"completion":1169,"start":1170,"enrollment":9,"conditions":1192,"interventions":1193},[62,63],[1172],[1157,1174,1175],{"trials":1195,"activeCount":73},[],{"trials":1197,"activeCount":73},[],{"trials":1199,"activeCount":73},[],{"intervention":1175,"totalTrials":69,"cells":1201},{"EARLY_PHASE1":1202,"PHASE1":1204,"PHASE2":1206,"PHASE3":1212,"PHASE4":1214,"NA":1216},{"trials":1203,"activeCount":73},[],{"trials":1205,"activeCount":73},[],{"trials":1207,"activeCount":73},[1208],{"nctId":1166,"briefTitle":1167,"status":317,"phases":1209,"primaryCompletion":1169,"completion":1169,"start":1170,"enrollment":9,"conditions":1210,"interventions":1211},[62,63],[1172],[1157,1174,1175],{"trials":1213,"activeCount":73},[],{"trials":1215,"activeCount":73},[],{"trials":1217,"activeCount":73},[],{"intervention":1219,"totalTrials":69,"cells":1220},"RAD001",{"EARLY_PHASE1":1221,"PHASE1":1223,"PHASE2":1225,"PHASE3":1236,"PHASE4":1238,"NA":1240},{"trials":1222,"activeCount":73},[],{"trials":1224,"activeCount":73},[],{"trials":1226,"activeCount":73},[1227],{"nctId":1228,"briefTitle":1229,"status":116,"phases":1230,"primaryCompletion":1231,"completion":753,"start":1232,"enrollment":244,"conditions":1233,"interventions":1235},"NCT00714025","A Single Arm, Multicenter, Phase II Trial of RAD001 as Monotherapy in the Palliative Treatment of Patients With TCC After Failure of Chemotherapy",[63],"2009-04","2008-11",[1234],"Transitional Cell Carcinoma",[1219],{"trials":1237,"activeCount":73},[],{"trials":1239,"activeCount":73},[],{"trials":1241,"activeCount":73},[],{"intervention":1243,"totalTrials":69,"cells":1244},"Vaccine MAGE-3.A1 peptide, or the NA17.A2 peptide + IL-2, IFN-α and GMCSF, Imiquimod.",{"EARLY_PHASE1":1245,"PHASE1":1247,"PHASE2":1249,"PHASE3":1260,"PHASE4":1262,"NA":1264},{"trials":1246,"activeCount":73},[],{"trials":1248,"activeCount":73},[],{"trials":1250,"activeCount":73},[1251],{"nctId":1252,"briefTitle":1253,"status":317,"phases":1254,"primaryCompletion":1255,"completion":1256,"start":1257,"enrollment":94,"conditions":1258,"interventions":1259},"NCT01191034","Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma",[62,63],"2012-08","2012-08-01","2010-08",[1172],[1243],{"trials":1261,"activeCount":73},[],{"trials":1263,"activeCount":73},[],{"trials":1265,"activeCount":73},[],{"intervention":1267,"totalTrials":69,"cells":1268},"BEZ235",{"EARLY_PHASE1":1269,"PHASE1":1271,"PHASE2":1273,"PHASE3":1283,"PHASE4":1285,"NA":1287},{"trials":1270,"activeCount":73},[],{"trials":1272,"activeCount":73},[],{"trials":1274,"activeCount":73},[1275],{"nctId":1276,"briefTitle":1277,"status":317,"phases":1278,"primaryCompletion":587,"completion":587,"start":1279,"enrollment":916,"conditions":1280,"interventions":1282},"NCT01856101","Study of BEZ235 as Monotherapy in Patients With Transitional Cell Carcinoma After Failure of Platinum Based Chemotherapy",[63],"2013-02",[1281],"Carcinoma Transitional Cell",[1267],{"trials":1284,"activeCount":73},[],{"trials":1286,"activeCount":73},[],{"trials":1288,"activeCount":73},[],{"intervention":654,"totalTrials":69,"cells":1290},{"EARLY_PHASE1":1291,"PHASE1":1293,"PHASE2":1295,"PHASE3":1301,"PHASE4":1303,"NA":1305},{"trials":1292,"activeCount":73},[],{"trials":1294,"activeCount":73},[],{"trials":1296,"activeCount":73},[1297],{"nctId":648,"briefTitle":649,"status":317,"phases":1298,"primaryCompletion":651,"completion":651,"start":587,"enrollment":31,"conditions":1299,"interventions":1300},[63],[631],[654,655,635,615,646],{"trials":1302,"activeCount":73},[],{"trials":1304,"activeCount":73},[],{"trials":1306,"activeCount":73},[],{"intervention":655,"totalTrials":69,"cells":1308},{"EARLY_PHASE1":1309,"PHASE1":1311,"PHASE2":1313,"PHASE3":1319,"PHASE4":1321,"NA":1323},{"trials":1310,"activeCount":73},[],{"trials":1312,"activeCount":73},[],{"trials":1314,"activeCount":73},[1315],{"nctId":648,"briefTitle":649,"status":317,"phases":1316,"primaryCompletion":651,"completion":651,"start":587,"enrollment":31,"conditions":1317,"interventions":1318},[63],[631],[654,655,635,615,646],{"trials":1320,"activeCount":73},[],{"trials":1322,"activeCount":73},[],{"trials":1324,"activeCount":73},[],{"intervention":1326,"totalTrials":69,"cells":1327},"infusions of Panitumumab",{"EARLY_PHASE1":1328,"PHASE1":1330,"PHASE2":1332,"PHASE3":1341,"PHASE4":1343,"NA":1345},{"trials":1329,"activeCount":73},[],{"trials":1331,"activeCount":73},[],{"trials":1333,"activeCount":73},[1334],{"nctId":1335,"briefTitle":1336,"status":344,"phases":1337,"primaryCompletion":1338,"completion":1338,"start":1257,"enrollment":781,"conditions":1339,"interventions":1340},"NCT01129154","Panitumumab (Vectibix®) in Cutaneous Squamous Cell Carcinoma (SCC)",[63],"2012-07",[918],[1326],{"trials":1342,"activeCount":73},[],{"trials":1344,"activeCount":73},[],{"trials":1346,"activeCount":73},[],{"intervention":1348,"totalTrials":69,"cells":1349},"gemcitabine + cetuximab",{"EARLY_PHASE1":1350,"PHASE1":1352,"PHASE2":1354,"PHASE3":1365,"PHASE4":1367,"NA":1369},{"trials":1351,"activeCount":73},[],{"trials":1353,"activeCount":73},[],{"trials":1355,"activeCount":73},[1356],{"nctId":1357,"briefTitle":1358,"status":116,"phases":1359,"primaryCompletion":890,"completion":890,"start":1360,"enrollment":1361,"conditions":1362,"interventions":1364},"NCT00747097","Gemcitabine and Cetuximab in Patients With Advanced or Metastatic Biliary Tract Cancer: A Multicenter Phase II Study",[63],"2008-09",43,[1363],"Time to Progression",[1348],{"trials":1366,"activeCount":73},[],{"trials":1368,"activeCount":73},[],{"trials":1370,"activeCount":73},[],{"intervention":1372,"totalTrials":69,"cells":1373},"Celecoxib 400 mg",{"EARLY_PHASE1":1374,"PHASE1":1376,"PHASE2":1378,"PHASE3":1390,"PHASE4":1392,"NA":1394},{"trials":1375,"activeCount":73},[],{"trials":1377,"activeCount":73},[],{"trials":1379,"activeCount":73},[1380],{"nctId":1381,"briefTitle":1382,"status":344,"phases":1383,"primaryCompletion":1384,"completion":1384,"start":1385,"enrollment":1386,"conditions":1387,"interventions":1389},"NCT03864575","An Open Label Phase II Study Combining Nivolumab and Celecoxib in Patients With Advanced \" Cold \" Solid Tumors",[63],"2021-06-15","2019-08-15",68,[1388],"Metastatic Cancer",[1372],{"trials":1391,"activeCount":73},[],{"trials":1393,"activeCount":73},[],{"trials":1395,"activeCount":73},[],{"intervention":1397,"totalTrials":69,"cells":1398},"Cabazitaxel",{"EARLY_PHASE1":1399,"PHASE1":1401,"PHASE2":1403,"PHASE3":1416,"PHASE4":1418,"NA":1420},{"trials":1400,"activeCount":73},[],{"trials":1402,"activeCount":73},[],{"trials":1404,"activeCount":73},[1405],{"nctId":1406,"briefTitle":1407,"status":116,"phases":1408,"primaryCompletion":1409,"completion":1409,"start":1410,"enrollment":1411,"conditions":1412,"interventions":1414},"NCT01528163","Study Comparing Two Treatments in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck",[63],"2014-11","2012-02",101,[1413],"Squamous Cell Carcinoma of the Head and Neck",[1397,1415],"Methotrexate",{"trials":1417,"activeCount":73},[],{"trials":1419,"activeCount":73},[],{"trials":1421,"activeCount":73},[],{"intervention":1415,"totalTrials":69,"cells":1423},{"EARLY_PHASE1":1424,"PHASE1":1426,"PHASE2":1428,"PHASE3":1434,"PHASE4":1436,"NA":1438},{"trials":1425,"activeCount":73},[],{"trials":1427,"activeCount":73},[],{"trials":1429,"activeCount":73},[1430],{"nctId":1406,"briefTitle":1407,"status":116,"phases":1431,"primaryCompletion":1409,"completion":1409,"start":1410,"enrollment":1411,"conditions":1432,"interventions":1433},[63],[1413],[1397,1415],{"trials":1435,"activeCount":73},[],{"trials":1437,"activeCount":73},[],{"trials":1439,"activeCount":73},[],{"intervention":1441,"totalTrials":69,"cells":1442},"Vardenafil",{"EARLY_PHASE1":1443,"PHASE1":1445,"PHASE2":1447,"PHASE3":1458,"PHASE4":1460,"NA":1462},{"trials":1444,"activeCount":73},[],{"trials":1446,"activeCount":73},[],{"trials":1448,"activeCount":73},[1449],{"nctId":1450,"briefTitle":1451,"status":317,"phases":1452,"primaryCompletion":1453,"completion":1454,"start":1455,"enrollment":26,"conditions":1456,"interventions":1457},"NCT01002534","Does a Nasal Instillation of Vardenafil Normalize the Nasal Potential Difference in Cystic Fibrosis Patients?",[63],"2012-06","2018-03","2011-10",[17],[1441],{"trials":1459,"activeCount":73},[],{"trials":1461,"activeCount":73},[],{"trials":1463,"activeCount":73},[],{"intervention":1465,"totalTrials":69,"cells":1466},"valproic acid and 2-chlorodeoxyadenosine",{"EARLY_PHASE1":1467,"PHASE1":1469,"PHASE2":1471,"PHASE3":1483,"PHASE4":1485,"NA":1487},{"trials":1468,"activeCount":73},[],{"trials":1470,"activeCount":73},[],{"trials":1472,"activeCount":73},[1473],{"nctId":1474,"briefTitle":1475,"status":344,"phases":1476,"primaryCompletion":1477,"completion":1477,"start":1478,"enrollment":1479,"conditions":1480,"interventions":1482},"NCT01295593","Low Dose CdA Combined With Valproic Acid (VPA) in Previously Treated B-cell Chronic Lymphocytic Leukemia(B-CLL)",[62,63],"2013-04","2010-12",33,[1481],"Chronic Lymphocytic Leukemia",[1465],{"trials":1484,"activeCount":73},[],{"trials":1486,"activeCount":73},[],{"trials":1488,"activeCount":73},[],{"intervention":1490,"totalTrials":69,"cells":1491},"Rituximab",{"EARLY_PHASE1":1492,"PHASE1":1494,"PHASE2":1496,"PHASE3":1505,"PHASE4":1507,"NA":1509},{"trials":1493,"activeCount":73},[],{"trials":1495,"activeCount":73},[],{"trials":1497,"activeCount":73},[1498],{"nctId":1499,"briefTitle":1500,"status":317,"phases":1501,"primaryCompletion":1502,"completion":1502,"start":1338,"enrollment":9,"conditions":1503,"interventions":1504},"NCT01625741","Phase II Study of High-Dose Rituximab in High-Risk Chronic Lymphocytic Leukemia Patients in Suboptimal Response After Induction Immunochemotherapy",[63],"2015-05",[1481],[1490],{"trials":1506,"activeCount":73},[],{"trials":1508,"activeCount":73},[],{"trials":1510,"activeCount":73},[],{"intervention":1512,"totalTrials":69,"cells":1513},"Empagliflozin",{"EARLY_PHASE1":1514,"PHASE1":1516,"PHASE2":1518,"PHASE3":1530,"PHASE4":1532,"NA":1534},{"trials":1515,"activeCount":73},[],{"trials":1517,"activeCount":73},[],{"trials":1519,"activeCount":73},[1520],{"nctId":1521,"briefTitle":1522,"status":344,"phases":1523,"primaryCompletion":1524,"completion":1524,"start":1525,"enrollment":26,"conditions":1526,"interventions":1529},"NCT04138251","Safety, Efficacy Evaluation of Empagliflozin Administration for Neutropenia in Glycogenosis Type 1b and G6PC3 Deficiency",[63],"2020-06-30","2019-06-20",[1527,1528],"Glycogen Storage Disease Type I","Glucose 6 Phosphatase Deficiency",[1512],{"trials":1531,"activeCount":73},[],{"trials":1533,"activeCount":73},[],{"trials":1535,"activeCount":73},[],{"intervention":1537,"totalTrials":69,"cells":1538},"Oral C13",{"EARLY_PHASE1":1539,"PHASE1":1541,"PHASE2":1543,"PHASE3":1552,"PHASE4":1554,"NA":1556},{"trials":1540,"activeCount":73},[],{"trials":1542,"activeCount":73},[],{"trials":1544,"activeCount":73},[1545],{"nctId":1546,"briefTitle":1547,"status":344,"phases":1548,"primaryCompletion":321,"start":753,"enrollment":418,"conditions":1549,"interventions":1551},"NCT01560897","Investigating Project of the Functional C13 Test \"Pilot Study\"",[62,63],[1550],"Disorder of the Urea Cycle",[1537],{"trials":1553,"activeCount":73},[],{"trials":1555,"activeCount":73},[],{"trials":1557,"activeCount":73},[],{"intervention":1559,"totalTrials":69,"cells":1560},"Celecoxib 200mg",{"EARLY_PHASE1":1561,"PHASE1":1563,"PHASE2":1565,"PHASE3":1577,"PHASE4":1579,"NA":1581},{"trials":1562,"activeCount":73},[],{"trials":1564,"activeCount":73},[],{"trials":1566,"activeCount":73},[1567],{"nctId":1568,"briefTitle":1569,"status":344,"phases":1570,"primaryCompletion":1571,"completion":1571,"start":1572,"enrollment":1573,"conditions":1574,"interventions":1576},"NCT03896113","Neoadjuvant Celecoxib in Newly Diagnosed Patients With Endometrial Carcinoma",[63],"2022-06-30","2019-11-13",48,[1575],"Endometrium Cancer",[1559],{"trials":1578,"activeCount":73},[],{"trials":1580,"activeCount":73},[],{"trials":1582,"activeCount":73},[],{"intervention":1584,"totalTrials":69,"cells":1585},"LEE011",{"EARLY_PHASE1":1586,"PHASE1":1588,"PHASE2":1600,"PHASE3":1602,"PHASE4":1604,"NA":1606},{"trials":1587,"activeCount":73},[],{"trials":1589,"activeCount":73},[1590],{"nctId":1591,"briefTitle":1592,"status":317,"phases":1593,"primaryCompletion":1594,"completion":1595,"start":1596,"enrollment":1597,"conditions":1598,"interventions":1599},"NCT02429089","Study of LEE011plus Cetuximab in Patients With a Cancer of the Head and Neck",[62],"2017-09-01","2018-09-01","2015-04",21,[1413],[1584],{"trials":1601,"activeCount":73},[],{"trials":1603,"activeCount":73},[],{"trials":1605,"activeCount":73},[],{"trials":1607,"activeCount":73},[],{"intervention":1609,"totalTrials":69,"cells":1610},"sorafenib (200 or 400mg bid) and taxotere iv",{"EARLY_PHASE1":1611,"PHASE1":1613,"PHASE2":1627,"PHASE3":1629,"PHASE4":1631,"NA":1633},{"trials":1612,"activeCount":73},[],{"trials":1614,"activeCount":73},[1615],{"nctId":1616,"briefTitle":1617,"status":116,"phases":1618,"primaryCompletion":1619,"completion":1620,"start":1621,"enrollment":1622,"conditions":1623,"interventions":1626},"NCT00405210","Pharmacokinetic Study of BAY43-9006 and Taxotere to Treat Patient With Prostatic Cancer",[62],"2008-08","2009-12","2006-09",38,[1624,1625],"Primary Disease","Prostate Cancer",[1609],{"trials":1628,"activeCount":73},[],{"trials":1630,"activeCount":73},[],{"trials":1632,"activeCount":73},[],{"trials":1634,"activeCount":73},[],{"intervention":1636,"totalTrials":69,"cells":1637},"Gallium-68 PSMA-11 prepared using PSMA-11 Sterile Cold Kit",{"EARLY_PHASE1":1638,"PHASE1":1640,"PHASE2":1651,"PHASE3":1653,"PHASE4":1655,"NA":1657},{"trials":1639,"activeCount":73},[],{"trials":1641,"activeCount":73},[1642],{"nctId":1643,"briefTitle":1644,"status":116,"phases":1645,"primaryCompletion":1646,"completion":1646,"start":1647,"enrollment":616,"conditions":1648,"interventions":1650},"NCT03183544","Dosimetry and Safety Phase 1 Study With 68Ga-PSMA-11 Sterile Cold Kit",[62],"2020-02-24","2019-01-24",[1649],"Prostatic Neoplasm",[1636],{"trials":1652,"activeCount":73},[],{"trials":1654,"activeCount":73},[],{"trials":1656,"activeCount":73},[],{"trials":1658,"activeCount":73},[],{"intervention":1660,"totalTrials":69,"cells":1661},"500mg Amikacine",{"EARLY_PHASE1":1662,"PHASE1":1672,"PHASE2":1674,"PHASE3":1676,"PHASE4":1678,"NA":1680},{"trials":1663,"activeCount":73},[1664],{"nctId":1665,"briefTitle":1666,"status":344,"phases":1667,"primaryCompletion":1668,"start":1669,"enrollment":418,"conditions":1670,"interventions":1671},"NCT02277808","Which Apparatus for Inhaled Pentamidine?",[61],"2014-10","2013-12",[14],[1660],{"trials":1673,"activeCount":73},[],{"trials":1675,"activeCount":73},[],{"trials":1677,"activeCount":73},[],{"trials":1679,"activeCount":73},[],{"trials":1681,"activeCount":73},[],{"intervention":1683,"totalTrials":31,"cells":1684},"Technetium-99m - Diethylenetriaminepentaacetic acid",{"EARLY_PHASE1":1685,"PHASE1":1687,"PHASE2":1689,"PHASE3":1691,"PHASE4":1693,"NA":1695},{"trials":1686,"activeCount":73},[],{"trials":1688,"activeCount":73},[],{"trials":1690,"activeCount":73},[],{"trials":1692,"activeCount":73},[],{"trials":1694,"activeCount":73},[],{"trials":1696,"activeCount":73},[1697,1704,1713,1721],{"nctId":1698,"briefTitle":1699,"status":116,"phases":1700,"primaryCompletion":1701,"completion":1701,"start":1596,"enrollment":9,"conditions":1702,"interventions":1703},"NCT02429817","Tomographic Comparison of Aerosol Lung Distribution With Two Nebulizers Through a High Flow Nasal Cannula",[66],"2016-12",[14],[1683],{"nctId":1705,"briefTitle":1706,"status":116,"phases":1707,"primaryCompletion":1708,"completion":1708,"start":486,"enrollment":15,"conditions":1709,"interventions":1711},"NCT01879488","Effect of Ventilation Mode on Lung Deposition of a Radiolabeled Aerosol During Mechanical Ventilation: Barometric Versus Volumetric",[66],"2015-06",[1710],"Post-operative Neurosurgery",[1712],"technetium-99m - Diethylenetriaminepentaacetic acid",{"nctId":1714,"briefTitle":1715,"status":317,"phases":1716,"primaryCompletion":1717,"start":1718,"enrollment":963,"conditions":1719,"interventions":1720},"NCT02450279","Scintigraphic Comparison of Lung Deposition With Two Nebulizers During Invasive Mechanical Ventilation",[66],"2017-11-07","2016-03",[1710],[1712],{"nctId":1722,"briefTitle":1723,"status":116,"phases":1724,"primaryCompletion":1708,"start":485,"enrollment":9,"conditions":1725,"interventions":1726},"NCT02298101","Comparison of Lung Deposition With the Aeroneb Solo Adapter and a Standard Jet Nebulizer by SPECT-CT",[66],[14],[1683],{"intervention":1728,"totalTrials":69,"cells":1729},"blood samples, urine samples and nasopharyngeal swabs",{"EARLY_PHASE1":1730,"PHASE1":1732,"PHASE2":1734,"PHASE3":1736,"PHASE4":1738,"NA":1740},{"trials":1731,"activeCount":73},[],{"trials":1733,"activeCount":73},[],{"trials":1735,"activeCount":73},[],{"trials":1737,"activeCount":73},[],{"trials":1739,"activeCount":73},[],{"trials":1741,"activeCount":73},[1742],{"nctId":1743,"briefTitle":1744,"status":116,"phases":1745,"primaryCompletion":1746,"completion":1747,"start":1748,"enrollment":1749,"conditions":1750,"interventions":1753},"NCT05557539","Hypothesizing the Genesis of Infectious Diseases and Epidemics Through an Integrated Systems Biology Approach",[66],"2024-12-18","2025-06-30","2022-02-07",249,[1751,1752],"SARS-CoV-2 Infection","Influenza Viral Infections",[1728],{"intervention":1755,"totalTrials":69,"cells":1756},"Aerosoltherapy",{"EARLY_PHASE1":1757,"PHASE1":1759,"PHASE2":1761,"PHASE3":1763,"PHASE4":1765,"NA":1767},{"trials":1758,"activeCount":73},[],{"trials":1760,"activeCount":73},[],{"trials":1762,"activeCount":73},[],{"trials":1764,"activeCount":73},[],{"trials":1766,"activeCount":73},[],{"trials":1768,"activeCount":73},[1769],{"nctId":1770,"briefTitle":1771,"status":1772,"phases":1773,"primaryCompletion":1774,"completion":1774,"start":1775,"enrollment":73,"conditions":1776,"interventions":1777},"NCT03655249","Effects of AD on VI in Patients With CF","WITHDRAWN",[66],"2025-12","2018-08-01",[17],[1755],{"intervention":1779,"totalTrials":69,"cells":1780},"Insulin aspart, glargine and detemir",{"EARLY_PHASE1":1781,"PHASE1":1783,"PHASE2":1785,"PHASE3":1787,"PHASE4":1789,"NA":1791},{"trials":1782,"activeCount":73},[],{"trials":1784,"activeCount":73},[],{"trials":1786,"activeCount":73},[],{"trials":1788,"activeCount":73},[],{"trials":1790,"activeCount":73},[],{"trials":1792,"activeCount":73},[1793],{"nctId":1794,"briefTitle":1795,"status":116,"phases":1796,"primaryCompletion":1797,"completion":1798,"start":1799,"enrollment":1800,"conditions":1801,"interventions":1803},"NCT02824510","Evaluation of Glycemic Changes During Exercise in Children With Type 1 Diabetes",[66],"2016-09","2017-01","2014-08",24,[1802],"Type 1 Diabetes",[1779],{"intervention":1805,"totalTrials":69,"cells":1806},"neostigmine",{"EARLY_PHASE1":1807,"PHASE1":1809,"PHASE2":1811,"PHASE3":1813,"PHASE4":1815,"NA":1817},{"trials":1808,"activeCount":73},[],{"trials":1810,"activeCount":73},[],{"trials":1812,"activeCount":73},[],{"trials":1814,"activeCount":73},[],{"trials":1816,"activeCount":73},[],{"trials":1818,"activeCount":73},[1819],{"nctId":1820,"briefTitle":1821,"status":344,"phases":1822,"completion":1823,"start":1824,"enrollment":487,"conditions":1825,"interventions":1828},"NCT00407290","The Impact of an Epidural Ropivacaine-Neostigmine Injection for Perineal Analgesia at the End of Labor.",[66],"2006-10","2006-03",[1826,1827],"Pregnancy","Vaginal Delivery",[1805],{"intervention":1830,"totalTrials":69,"cells":1831},"Apolipoprotein genotype",{"EARLY_PHASE1":1832,"PHASE1":1834,"PHASE2":1836,"PHASE3":1838,"PHASE4":1840,"NA":1842},{"trials":1833,"activeCount":73},[],{"trials":1835,"activeCount":73},[],{"trials":1837,"activeCount":73},[],{"trials":1839,"activeCount":73},[],{"trials":1841,"activeCount":73},[],{"trials":1843,"activeCount":73},[1844],{"nctId":1845,"briefTitle":1846,"status":116,"phases":1847,"primaryCompletion":1848,"completion":1849,"start":1850,"enrollment":1851,"conditions":1852,"interventions":1854},"NCT03706989","Predicting Postoperative Delirium Using EEG, Genetics and Neurobiomarkers of Cerebral Injury",[66],"2021-12-15","2022-06-15","2019-05-15",387,[1853],"Postoperative Delirium",[1830,1855],"Serum NfL measurements",{"intervention":1855,"totalTrials":69,"cells":1857},{"EARLY_PHASE1":1858,"PHASE1":1860,"PHASE2":1862,"PHASE3":1864,"PHASE4":1866,"NA":1868},{"trials":1859,"activeCount":73},[],{"trials":1861,"activeCount":73},[],{"trials":1863,"activeCount":73},[],{"trials":1865,"activeCount":73},[],{"trials":1867,"activeCount":73},[],{"trials":1869,"activeCount":73},[1870],{"nctId":1845,"briefTitle":1846,"status":116,"phases":1871,"primaryCompletion":1848,"completion":1849,"start":1850,"enrollment":1851,"conditions":1872,"interventions":1873},[66],[1853],[1830,1855],{"intervention":1875,"totalTrials":69,"cells":1876},"Hydroxyethylstarch 6% 130\u002F0.4",{"EARLY_PHASE1":1877,"PHASE1":1879,"PHASE2":1881,"PHASE3":1883,"PHASE4":1885,"NA":1887},{"trials":1878,"activeCount":73},[],{"trials":1880,"activeCount":73},[],{"trials":1882,"activeCount":73},[],{"trials":1884,"activeCount":73},[],{"trials":1886,"activeCount":73},[],{"trials":1888,"activeCount":73},[1889],{"nctId":1890,"briefTitle":1891,"status":116,"phases":1892,"primaryCompletion":1477,"completion":1477,"start":752,"enrollment":1893,"conditions":1894,"interventions":1896},"NCT02306213","Effect of Hydroxyethylstarch 6% 130\u002F0.4 Administration on Renal Function After Cardiac Surgery",[66],1564,[1895],"Kidney Function Tests",[1875],{"intervention":1898,"totalTrials":69,"cells":1899},"Dolutegravir",{"EARLY_PHASE1":1900,"PHASE1":1902,"PHASE2":1904,"PHASE3":1906,"PHASE4":1908,"NA":1910},{"trials":1901,"activeCount":73},[],{"trials":1903,"activeCount":73},[],{"trials":1905,"activeCount":73},[],{"trials":1907,"activeCount":73},[],{"trials":1909,"activeCount":73},[],{"trials":1911,"activeCount":73},[1912],{"nctId":1913,"briefTitle":1914,"status":116,"phases":1915,"primaryCompletion":370,"completion":370,"start":1916,"enrollment":1917,"conditions":1918,"interventions":1920},"NCT04805944","Gut Microbiota, PGx and INSTIs Response",[],"2021-03-10",180,[1919],"HIV Infections",[1898,1921,1898,1898,1921],"Bictegravir",{"intervention":1921,"totalTrials":69,"cells":1923},{"EARLY_PHASE1":1924,"PHASE1":1926,"PHASE2":1928,"PHASE3":1930,"PHASE4":1932,"NA":1934},{"trials":1925,"activeCount":73},[],{"trials":1927,"activeCount":73},[],{"trials":1929,"activeCount":73},[],{"trials":1931,"activeCount":73},[],{"trials":1933,"activeCount":73},[],{"trials":1935,"activeCount":73},[1936],{"nctId":1913,"briefTitle":1914,"status":116,"phases":1937,"primaryCompletion":370,"completion":370,"start":1916,"enrollment":1917,"conditions":1938,"interventions":1939},[],[1919],[1898,1921,1898,1898,1921],{"intervention":1941,"totalTrials":69,"cells":1942},"quetiapine or olanzapine or risperidone or aripiprazole",{"EARLY_PHASE1":1943,"PHASE1":1945,"PHASE2":1947,"PHASE3":1949,"PHASE4":1951,"NA":1953},{"trials":1944,"activeCount":73},[],{"trials":1946,"activeCount":73},[],{"trials":1948,"activeCount":73},[],{"trials":1950,"activeCount":73},[],{"trials":1952,"activeCount":73},[],{"trials":1954,"activeCount":73},[1955],{"nctId":1956,"briefTitle":1957,"status":116,"phases":1958,"completion":1089,"start":1959,"enrollment":1960,"conditions":1961,"interventions":1963},"NCT00528359","β-Cell Function in Schizophrenic Subjects on Atypical Antipsychotic drugS",[],"2005-10",36,[1962],"Schizophrenia",[1941],{"intervention":1965,"totalTrials":69,"cells":1966},"amikacine nebulization",{"EARLY_PHASE1":1967,"PHASE1":1969,"PHASE2":1971,"PHASE3":1973,"PHASE4":1975,"NA":1977},{"trials":1968,"activeCount":73},[],{"trials":1970,"activeCount":73},[],{"trials":1972,"activeCount":73},[],{"trials":1974,"activeCount":73},[],{"trials":1976,"activeCount":73},[],{"trials":1978,"activeCount":73},[1979],{"nctId":1980,"briefTitle":1981,"status":344,"phases":1982,"primaryCompletion":1983,"completion":1984,"start":1985,"enrollment":1986,"conditions":1987,"interventions":1989},"NCT02535130","Evaluation of Nebulization and Positive Expiratory Pressure Combination",[66],"2016-08","2018-06","2015-08",15,[17,1988],"Healthy Subjects",[1965],{"intervention":1991,"totalTrials":69,"cells":1992},"GLP-1 analog",{"EARLY_PHASE1":1993,"PHASE1":1995,"PHASE2":1997,"PHASE3":1999,"PHASE4":2001,"NA":2003},{"trials":1994,"activeCount":73},[],{"trials":1996,"activeCount":73},[],{"trials":1998,"activeCount":73},[],{"trials":2000,"activeCount":73},[],{"trials":2002,"activeCount":73},[],{"trials":2004,"activeCount":73},[2005],{"nctId":2006,"briefTitle":2007,"status":116,"phases":2008,"primaryCompletion":321,"completion":2009,"start":753,"enrollment":418,"conditions":2010,"interventions":2013},"NCT01687582","Effect of GLP-1 Analogs on Psoriasis in Type 2 Diabetic Patients",[66],"2013-03",[2011,2012],"Type 2 Diabetes","Psoriasis",[1991],{"intervention":2015,"totalTrials":69,"cells":2016},"Budesonide novolizer",{"EARLY_PHASE1":2017,"PHASE1":2019,"PHASE2":2021,"PHASE3":2023,"PHASE4":2025,"NA":2027},{"trials":2018,"activeCount":73},[],{"trials":2020,"activeCount":73},[],{"trials":2022,"activeCount":73},[],{"trials":2024,"activeCount":73},[],{"trials":2026,"activeCount":73},[],{"trials":2028,"activeCount":73},[2029],{"nctId":2030,"briefTitle":2031,"status":344,"phases":2032,"primaryCompletion":242,"completion":2033,"start":1718,"enrollment":373,"conditions":2034,"interventions":2035},"NCT02715167","Predictive Factors in Response to Inhaled Corticoids in Chronic Cough",[66],"2017-12",[14],[2015],{"intervention":2037,"totalTrials":69,"cells":2038},"Saliva sample collection for genetic analyses",{"EARLY_PHASE1":2039,"PHASE1":2041,"PHASE2":2043,"PHASE3":2045,"PHASE4":2047,"NA":2049},{"trials":2040,"activeCount":73},[],{"trials":2042,"activeCount":73},[],{"trials":2044,"activeCount":73},[],{"trials":2046,"activeCount":73},[],{"trials":2048,"activeCount":73},[],{"trials":2050,"activeCount":73},[2051],{"nctId":2052,"briefTitle":2053,"status":344,"phases":2054,"primaryCompletion":2055,"completion":2055,"start":1477,"enrollment":109,"conditions":2056,"interventions":2057},"NCT02440802","Evaluation and Predictive Value of Genetic Polymorphisms in the Management of Hormonal Treatment of Prostate Cancer",[],"2017-09",[1625],[2037],{"intervention":2059,"totalTrials":69,"cells":2060},"Implement haemostatic non substitutive care of haemophilia",{"EARLY_PHASE1":2061,"PHASE1":2063,"PHASE2":2065,"PHASE3":2067,"PHASE4":2069,"NA":2071},{"trials":2062,"activeCount":73},[],{"trials":2064,"activeCount":73},[],{"trials":2066,"activeCount":73},[],{"trials":2068,"activeCount":73},[],{"trials":2070,"activeCount":73},[],{"trials":2072,"activeCount":73},[2073],{"nctId":2074,"briefTitle":2075,"status":116,"phases":2076,"primaryCompletion":2077,"completion":2078,"start":2079,"enrollment":2080,"conditions":2081,"interventions":2084},"NCT03054662","Non Substitutive Strategies to Improve Haemophilia Care in Developing Countries. Experience in Ivory Coast.",[66],"2018-12-31","2019-09-17","2017-01-16",142,[2082,2083],"Haemophilia","Developing Countries",[2059],{"intervention":2086,"totalTrials":69,"cells":2087},"Amikacin nebulization",{"EARLY_PHASE1":2088,"PHASE1":2090,"PHASE2":2092,"PHASE3":2094,"PHASE4":2096,"NA":2098},{"trials":2089,"activeCount":73},[],{"trials":2091,"activeCount":73},[],{"trials":2093,"activeCount":73},[],{"trials":2095,"activeCount":73},[],{"trials":2097,"activeCount":73},[],{"trials":2099,"activeCount":73},[2100],{"nctId":2101,"briefTitle":2102,"status":116,"phases":2103,"primaryCompletion":486,"completion":293,"start":2104,"enrollment":1986,"conditions":2105,"interventions":2106},"NCT02201082","Evaluation of the Timing of the Nebulization Related to the Physiotherapy Session",[66],"2012-09",[17],[2086],{"intervention":2108,"totalTrials":69,"cells":2109},"Levosimendan",{"EARLY_PHASE1":2110,"PHASE1":2112,"PHASE2":2114,"PHASE3":2116,"PHASE4":2118,"NA":2120},{"trials":2111,"activeCount":73},[],{"trials":2113,"activeCount":73},[],{"trials":2115,"activeCount":73},[],{"trials":2117,"activeCount":73},[],{"trials":2119,"activeCount":73},[],{"trials":2121,"activeCount":73},[2122],{"nctId":2123,"briefTitle":2124,"status":116,"phases":2125,"primaryCompletion":962,"completion":2126,"start":269,"enrollment":510,"conditions":2127,"interventions":2130},"NCT00695929","Levosimendan in Congenital Cardiac Surgery",[66],"2009-10",[2128,2129],"Congenital Cardiovascular Defects","Low Cardiac Output Syndrome",[2108,2131],"Milrinone",{"intervention":2131,"totalTrials":69,"cells":2133},{"EARLY_PHASE1":2134,"PHASE1":2136,"PHASE2":2138,"PHASE3":2140,"PHASE4":2142,"NA":2144},{"trials":2135,"activeCount":73},[],{"trials":2137,"activeCount":73},[],{"trials":2139,"activeCount":73},[],{"trials":2141,"activeCount":73},[],{"trials":2143,"activeCount":73},[],{"trials":2145,"activeCount":73},[2146],{"nctId":2123,"briefTitle":2124,"status":116,"phases":2147,"primaryCompletion":962,"completion":2126,"start":269,"enrollment":510,"conditions":2148,"interventions":2149},[66],[2128,2129],[2108,2131],{"intervention":2151,"totalTrials":69,"cells":2152},"Genetic signature",{"EARLY_PHASE1":2153,"PHASE1":2155,"PHASE2":2157,"PHASE3":2159,"PHASE4":2161,"NA":2163},{"trials":2154,"activeCount":73},[],{"trials":2156,"activeCount":73},[],{"trials":2158,"activeCount":73},[],{"trials":2160,"activeCount":73},[],{"trials":2162,"activeCount":73},[],{"trials":2164,"activeCount":73},[2165],{"nctId":2166,"briefTitle":2167,"status":344,"phases":2168,"primaryCompletion":2169,"completion":2169,"start":2170,"enrollment":2171,"conditions":2172,"interventions":2174},"NCT03314870","Development of a Response Signature to Neoadjuvant Chemotherapy for Breast Cancer",[66],"2019-12-31","2017-08-07",220,[2173],"Breast Cancer",[2151],{"intervention":2176,"totalTrials":69,"cells":2177},"Povidone-Iodine 10%",{"EARLY_PHASE1":2178,"PHASE1":2180,"PHASE2":2182,"PHASE3":2184,"PHASE4":2186,"NA":2188},{"trials":2179,"activeCount":73},[],{"trials":2181,"activeCount":73},[],{"trials":2183,"activeCount":73},[],{"trials":2185,"activeCount":73},[],{"trials":2187,"activeCount":73},[],{"trials":2189,"activeCount":73},[2190],{"nctId":2191,"briefTitle":2192,"status":344,"phases":2193,"primaryCompletion":2194,"completion":2194,"start":2195,"enrollment":963,"conditions":2196,"interventions":2198},"NCT03432975","Evaluation of Multiple Subgingival Irrigations.",[66],"2019-08-31","2017-12-18",[2197],"Periodontitis, Adult",[2176,2199],"Saline Solution",{"intervention":2199,"totalTrials":69,"cells":2201},{"EARLY_PHASE1":2202,"PHASE1":2204,"PHASE2":2206,"PHASE3":2208,"PHASE4":2210,"NA":2212},{"trials":2203,"activeCount":73},[],{"trials":2205,"activeCount":73},[],{"trials":2207,"activeCount":73},[],{"trials":2209,"activeCount":73},[],{"trials":2211,"activeCount":73},[],{"trials":2213,"activeCount":73},[2214],{"nctId":2191,"briefTitle":2192,"status":344,"phases":2215,"primaryCompletion":2194,"completion":2194,"start":2195,"enrollment":963,"conditions":2216,"interventions":2217},[66],[2197],[2176,2199],{"intervention":2219,"totalTrials":69,"cells":2220},"Xeomin Injectable Product",{"EARLY_PHASE1":2221,"PHASE1":2223,"PHASE2":2225,"PHASE3":2227,"PHASE4":2229,"NA":2231},{"trials":2222,"activeCount":73},[],{"trials":2224,"activeCount":73},[],{"trials":2226,"activeCount":73},[],{"trials":2228,"activeCount":73},[],{"trials":2230,"activeCount":73},[],{"trials":2232,"activeCount":73},[2233],{"nctId":2234,"briefTitle":2235,"status":116,"phases":2236,"primaryCompletion":2237,"completion":2237,"start":2238,"enrollment":2239,"conditions":2240,"interventions":2241},"NCT04544280","Effect of Repeated Injections of Higher Doses of Botulinum Toxin on Lower Limb of Spastic Hemiplegic Patients on Gait.",[66],"2021-12-31","2018-09-13",32,[20],[2219],{"intervention":2243,"totalTrials":69,"cells":2244},"Metronidazole",{"EARLY_PHASE1":2245,"PHASE1":2247,"PHASE2":2249,"PHASE3":2251,"PHASE4":2253,"NA":2255},{"trials":2246,"activeCount":73},[],{"trials":2248,"activeCount":73},[],{"trials":2250,"activeCount":73},[],{"trials":2252,"activeCount":73},[],{"trials":2254,"activeCount":73},[],{"trials":2256,"activeCount":73},[2257],{"nctId":2258,"briefTitle":2259,"status":116,"phases":2260,"primaryCompletion":2261,"completion":2261,"start":118,"enrollment":1986,"conditions":2262,"interventions":2266},"NCT03069976","\"Overlap Syndrome and PSC: Evaluating Role of Gut Microflora and Its Identification With Antibiotics in Children\"",[66],"2021-08",[2263,2264,2265],"Primary Sclerosing Cholangitis","Autoimmune Hepatitis","Overlap Syndrome",[2243],{"intervention":2268,"totalTrials":69,"cells":2269},"Prophylaxis with Emicizumab",{"EARLY_PHASE1":2270,"PHASE1":2272,"PHASE2":2274,"PHASE3":2276,"PHASE4":2278,"NA":2280},{"trials":2271,"activeCount":73},[],{"trials":2273,"activeCount":73},[],{"trials":2275,"activeCount":73},[],{"trials":2277,"activeCount":73},[],{"trials":2279,"activeCount":73},[],{"trials":2281,"activeCount":73},[2282],{"nctId":2283,"briefTitle":2284,"status":116,"phases":2285,"primaryCompletion":2286,"completion":2286,"start":461,"enrollment":1479,"conditions":2287,"interventions":2289},"NCT05279924","Outcomes of Prophylaxis With Emicizumab in Children With Severe Hemophilia A in Ivory Coast",[66],"2022-10-20",[2288],"Hemophilia A",[2268],{"intervention":2291,"totalTrials":69,"cells":2292},"0.5% levobupivacaine injectable solution with 10 ml of physiological saline",{"EARLY_PHASE1":2293,"PHASE1":2295,"PHASE2":2297,"PHASE3":2299,"PHASE4":2301,"NA":2303},{"trials":2294,"activeCount":73},[],{"trials":2296,"activeCount":73},[],{"trials":2298,"activeCount":73},[],{"trials":2300,"activeCount":73},[],{"trials":2302,"activeCount":73},[],{"trials":2304,"activeCount":73},[2305],{"nctId":2306,"briefTitle":2307,"status":116,"phases":2308,"primaryCompletion":2309,"completion":2309,"start":1502,"enrollment":487,"conditions":2310,"interventions":2313},"NCT03110120","Interest of Serratus Plane Block in Postoperative Analgesia for Robot-assisted Surgery",[66],"2017-06",[2311,2312],"Analgesia","Robotic Surgery",[2291,2291,2314,2314],"0.5% levobupivacaine injectable solution with physiological saline",{"intervention":2314,"totalTrials":69,"cells":2316},{"EARLY_PHASE1":2317,"PHASE1":2319,"PHASE2":2321,"PHASE3":2323,"PHASE4":2325,"NA":2327},{"trials":2318,"activeCount":73},[],{"trials":2320,"activeCount":73},[],{"trials":2322,"activeCount":73},[],{"trials":2324,"activeCount":73},[],{"trials":2326,"activeCount":73},[],{"trials":2328,"activeCount":73},[2329],{"nctId":2306,"briefTitle":2307,"status":116,"phases":2330,"primaryCompletion":2309,"completion":2309,"start":1502,"enrollment":487,"conditions":2331,"interventions":2332},[66],[2311,2312],[2291,2291,2314,2314],{"intervention":2334,"totalTrials":69,"cells":2335},"tooth extraction with antibiotics",{"EARLY_PHASE1":2336,"PHASE1":2338,"PHASE2":2340,"PHASE3":2342,"PHASE4":2344,"NA":2346},{"trials":2337,"activeCount":73},[],{"trials":2339,"activeCount":73},[],{"trials":2341,"activeCount":73},[],{"trials":2343,"activeCount":73},[],{"trials":2345,"activeCount":73},[],{"trials":2347,"activeCount":73},[2348],{"nctId":2349,"briefTitle":2350,"status":344,"phases":2351,"primaryCompletion":118,"completion":1798,"start":587,"enrollment":373,"conditions":2352,"interventions":2354},"NCT02198001","Prospective Randomized Study: Assessment of PRF Efficacy in Prevention of Jaw Osteonecrosis After Tooth Extraction",[66],[2353],"Bisphosphonate-Associated Osteonecrosis of the Jaw",[2334]]